RGEN Raise ests and PT to $200 as Repligen continues to perform above heightened expectations and seemingly against a whack-a-mole of invest
RGEN Raise ests and PT to $200 as Repligen continues to perform above heightened expectations and seemingly against a whack-a-mole of investor fears @ DBAB
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.